Theragen Bio Co., Ltd. successfully analyzed the dielectric substances of COVID-19 and the patients on the largest scale in Korea

 Breaking News
  • No posts were found

Theragen Bio Co., Ltd. successfully analyzed the dielectric substances of COVID-19 and the patients on the largest scale in Korea

Theragen Bio Co., Ltd. identified genetic correlation while building the big data of the mutations and applying it to vaccine development.

In collaboration with Korea Research Institute of Chemical Technology, Kyungpook National University Hospital and Daegu City Hall, Theragen Bio has conducted a joint research for developing the big data of the dielectric substances of COVID-19.

The purpose of this research is to analyze the entire dielectric substance of each patient and SARS-CoV-2 using samples of about 1,000 patients with COVID-19 in Daegu and Gyeongsangbuk-do Province, which boasts the largest amount of the genetic analysis conducted in Korea.

Theragen Bio plans to use this research for identifying the infectious correlation on the dielectric substances between patients and COVID-19 to apply it to the development of vaccines in the future. 

Based on its own Next Generation Sequencing (NGS), the company uses the RNA analyzing system of COVID-19 to sequence about 30,000 whole RNA genomes per the virus. The virus is so unstable to cause frequent mutations. However, this research method will serve as a solution to check the variation, reproduction, and generation of the RNA.

In addition, the research will trace back the evolution of COVID-19 to identify the spreading cause between humans and predict clinical patterns, thereby selecting high-risk groups, improving the efficiency of PCR-based diagnosis, and securing evidence of the prevention strategies.

Hwang Tae-soon, CEO of Theragen Bio, explained, “This research is the first attempt to analyze whether there are differences in infection susceptibility depending on the genetic predisposition of the infected patients as well as the mutations and evolutions, and it will be applicable to various infectious diseases in the future as well as clinical prediction and vaccine development.”

Meanwhile, the company has participated in the study of high-resolution genetic map for SARS-CoV-2, which was developed in collaboration with V.Narry Kim, head of the RNA research group at Institute for Basic Science, Jang Hye-sik, a professor at Bioscience Department, Seoul National University, and National Institute of Health in April.

This study found the location of the gene and its variation in RNA to determine the transcriptome compositions and proliferation principles of the virus. In May, it also found that the patients with COVID-19 related to the club in Itaewon, Seoul, originated from the U.S., not from China. 

The company successfully traced the infection path by sequencing the dielectric substances and RNA transcriptomes of the confirmed at the club.

Theragen Bio was separated from Theragen Etex and was newly established in March under a plan to actively promote the projects related to new drugs using technology in the dielectric field.

Media Contact
Company Name: Theragen Bio Co., Ltd
Contact Person: Hyun Kim
Email: Send Email
Phone: +82-31-888-9313
Country: South Korea